Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10699124 | 0.82 | SOAT1 (0.69) | SOAT1 | |
| SCHEMBL9800926 | 0.79 | SOAT1 (0.66) | SOAT1 | |
| SCHEMBL9317529 | 0.78 | SOAT1 (0.64) | SOAT1 | |
| SCHEMBL9316540 | 0.78 | SOAT1 (0.64) | SOAT1 | |
| SCHEMBL9316620 | 0.78 | SOAT1 (0.64) | SOAT1 | |
| SCHEMBL9315973 | 0.78 | SOAT1 (0.64) | SOAT1 | |
| SCHEMBL9316503 | 0.78 | SOAT1 (0.64) | SOAT1 | |
| SCHEMBL9317566 | 0.78 | SOAT1 (0.64) | SOAT1 | |
| SCHEMBL9048460 | 0.75 | SOAT1 (0.60) | SOAT1 | |
| SCHEMBL28932540 | 0.75 | SOAT1 (0.59) | SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2453926-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | The Regents of the University of California (US) | 2012-05-23 | — | — | EP | claimed |
| WO-2011008996-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | claimed |
| WO-2010056910-A2 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-20050192245-A1 | Medicinal composition for treating arteriosclerosis | SANKYO COMPANY, LIMITED (JP) | 2005-09-01 | — | — | US | claimed |
| EP-1555032-A1 | MEDICINAL COMPOSITION FOR TREATING ARTERIOSCLEROSIS | Sankyo Company, Limited (JP) | 2005-07-20 | — | — | EP | claimed |
| US-20230279048-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2023-09-07 | — | — | US | disclosed |
| US-11518782-B2 | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | TISSUETECH, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| EP-3838293-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | Tissuetech, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| EP-2872181-B1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | TISSUETECH INC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200308219-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2020-10-01 | — | — | US | disclosed |
| US-10717763-B2 | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | TISSUETECH, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. | 2006-03-02 | — | — | US | disclosed |
| US-20050192245-A1 | Medicinal composition for treating arteriosclerosis | SANKYO COMPANY, LIMITED (JP) | 2005-09-01 | — | — | US | disclosed |
| EP-1555032-A1 | MEDICINAL COMPOSITION FOR TREATING ARTERIOSCLEROSIS | Sankyo Company, Limited (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005051298-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050119314-A1 | Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent | SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-1493448-A1 | MEDICINAL COMPOSITION COMPRISING ACAT INHIBITOR AND INSULINE RESISTANCE IMPROVING AGENT | Sankyo Company, Limited (JP) | 2005-01-05 | — | — | EP | disclosed |
| US-20040198788-A1 | Medicinal compositions containing angiotensin II receptor antagonist | SANKYO COMPANY, LIMITED (JP) | 2004-10-07 | — | — | US | disclosed |
| EP-1421953-A1 | MEDICINAL COMPOSITIONS CONTAINING ANGIOTENSIN II RECEPTOR ANTAGONIST | Sankyo Company, Limited (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | SOAT1 463/4885 |
| US-20040198788-A1 | Medicinal compositions containing angiotensin II receptor antagonist | AGTR2, AGTR1, AGT | SOAT1 419/4885 |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | PYGL, THRA, THOP1 | SOAT1 942/4885 |
| US-20050119314-A1 | Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent | ACAT2, ACAT1, ACACA | SOAT1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.